EGFR-based dual inhibitors: current status and perspectives

Future Med Chem. 2022 May;14(9):601-603. doi: 10.4155/fmc-2022-0007. Epub 2022 Mar 22.

Authors

Huan He¹, Baohui Qi^{1

2}

Affiliations

¹ Department of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, 519041, China.
² Key Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Zunyi Medical University, Zunyi, 563000, China.

PMID: 35315726
DOI: 10.4155/fmc-2022-0007

No abstract available

Keywords: EGFR; anticancer; dual inhibitors; non-small-cell lung cancers.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Cell Line, Tumor
Drug Resistance, Neoplasm
ErbB Receptors / genetics
Humans
Lung Neoplasms* / drug therapy
Mutation
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors